Alnylam Pharmaceuticals - 53 Year Dividend History | ALNY
Historical dividend payout and yield for Alnylam Pharmaceuticals (ALNY) since 1971. The current TTM dividend payout for Alnylam Pharmaceuticals (ALNY) as of April 25, 2024 is $0.00. The current dividend yield for Alnylam Pharmaceuticals as of April 25, 2024 is 0.00%.
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$18.111B |
$1.828B |
|
Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference. The company's pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas - genetic medicines, cardio-metabolic disease and hepatic infectious disease. The company's lead drug-Onpattro received regulatory approvals in the United States and Europe for the treatment of hereditary transthyretin-mediated amyloidosis in adults. The FDA approved Givlaari for acute hepatic porphyria. The FDA approved Oxlumo injection for subcutaneous use, for the treatment of primary hyperoxaluria type 1 to lower urinary oxalate levels in pediatric and adult patients. Moreover, the company is evaluating inclisiran for hypercholesterolemia in partnership with The Medicines Company acquired by Novartis. The FDA approved Leqvio to reduce low-density lipoprotein cholesterol with two doses a year..
|
| Stock Name |
Country |
Market Cap |
PE Ratio |
